SOURCE: GelStat Corporation

September 10, 2007 08:29 ET

GelStat Announces an International Distribution Agreement With Icarus Medical Industries

ST. PAUL, MN--(Marketwire - September 10, 2007) - GelStat Corporation (PINKSHEETS: GSAC), a consumer healthcare company primarily focused on the development and marketing of over-the-counter (OTC) products for the safe and effective treatment of pain and inflammation, is pleased to announce that Icarus Medical Industries has signed a five-year agreement to distribute GelStat's products throughout the Middle East.

Icarus Medical Industries, with offices in Springfield Gardens, New York, and Surra, Kuwait, is a leading distributor of medical products throughout the Middle East concentrating on pharmaceuticals, bio-medical and paramedical products. Under the terms of the agreement, Icarus will distribute Gelstat™ Migraine once the product receives approval from the Ministry of Health (MOH) which is expected in 60 to 90 days. Upon this approval, GelStat is guaranteed a substantial initial order.

Tom DeSantis of U.S. Marketing, the business development company hired by GelStat, said, "The entire GelStat team is very pleased to begin working with Icarus to bolster the distribution of GelStat Migraine and potentially increase the distribution of its other products currently in the pipeline. Our expectation is that the initial product launch will occur in the fourth quarter of 2007 and that its pricing will be similar to that in the U.S." Mr. DeSantis further stated, "This is the first international sales opportunity for GelStat™Migraine and opens the door for distribution in additional countries with product approval from the MOH."

Mr. Jim LaFlamme, Chairman and CEO of GelStat, stated, "Through the efforts of U.S. Marketing, this sets the stage to penetrate the international marketplace. Our migraine product has proven itself domestically and we are certain that it will attain the same results internationally. This agreement is another major step towards increasing the Company's brand recognition and revenue streams, while minimizing monthly expenses."

ABOUT GELSTAT CORPORATION

GelStat Corporation is dedicated to providing safe and effective over-the-counter (OTC) treatments for pain and inflammation. GelStat's first product, GelStat Migraine, is sold nationwide through retail chain stores, independent retailers and pharmacies, and direct to consumer channels. GelStat Migraine is a sublingually (under the tongue) administered OTC medication for acute relief from the pain and associated symptoms of migraine. Over 90 percent of the 30 million Americans with migraine use OTC headache remedies, generally aspirin or other non-steroidal anti-inflammatory drugs. Americans spend $2.6 billion each year on 600 million units of such products, although they are believed to be effective for only about 25 percent of those with moderate to severe migraine.

The Company also has a suite of additional, effective healthcare products that address large consumer markets. GelStat™ Arthritis is the second available product to utilize GelStat's patent-pending formulation and is provided as a daily use, sublingual dissolving tablet. The Center for Disease Control estimates that, in its many forms, arthritis affects up to 70 million Americans. The Company has also developed "GelStat™ Sinus" and "GelStat™ Sleep," and believes that each of these products performs well and is effective for its intended use. The National Institute of Allergy and Infectious Disease estimates that 37 million Americans are affected by sinusitis every year, with at least 20 million more suffering from allergies. Approximately 70 million Americans are reported to be "problem sleepers."

For more information, visit www.gelstat.com

Safe Harbor Statement Under the Private Securities Litigation Act of 1995

With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of GelStat could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rate and unanticipated events such as terrorist activities. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. For further risk factors, please review our SEC filings.

Contact Information